Opioid-Induced Sweating: What the Research Shows

How common is opioid-induced sweating?

Sweating is one of the more troublesome, though less-discussed, effects of opioid treatment. The best-quantified figure comes from methadone: a widely cited clinical survey by Al-Adwani and Basu (2004) reported that excessive sweating affected up to about 45% of patients on methadone-maintenance treatment, a rate confirmed as the reference point in later case literature (Hong 2017).

Outside methadone, precise class-wide percentages are scarce. Large opioid adverse-event studies in cancer pain tend to track constipation, nausea, drowsiness and delirium rather than sweating, so a clean incidence figure for morphine, oxycodone or fentanyl specifically is not well established. What the literature does agree on is that sweating occurs across opioids and can be difficult to attribute to any single drug.

The table gathers the figures that can be traced to a source. Note the different populations, a methadone clinic is not the same as a general hospice ward, so these numbers describe different questions, not competing estimates of one thing.

Why opioids cause sweating

Two mechanisms are proposed, and they are not mutually exclusive. The first is histamine release: opioids can trigger mast-cell degranulation and histamine release, which the original methadone report linked to flushing and sweating. The second is a central thermoregulatory effect: opioids appear to modulate the brain's temperature set-point, with acetylcholine acting at the sweat glands as the final mediator. Support for the second pathway comes from the observation that anticholinergic (antimuscarinic) drugs such as oxybutynin can suppress the sweating.

Acetylcholine is the principal neurotransmitter at eccrine sweat glands, which is why medicines that raise cholinergic tone, or that push the central thermostat, tend to increase sweating.

Sweating in pain and palliative care

In advanced cancer and hospice care, sweating is a genuine burden even though it is easy to overlook next to pain or breathlessness. In a study of 100 hospice admissions, 16 patients raised sweating unprompted, and for 12 of them it was severe enough to require changes of clothing or bedding (Quigley & Baines 1997).

Opioids are one of several contributors here (advanced disease, fever, and the cancer itself all drive sweating too), which is why clinicians often note that switching between opioids ("opioid rotation") rarely resolves the sweating on its own, since the effect is shared across the class. Antimuscarinic agents such as hyoscine (scopolamine) and oxybutynin have been described in case reports as symptom-directed options.

How to read these numbers

The dependable takeaways are qualitative. Sweating is a recognized effect across opioids; it is best quantified for methadone, where roughly two-fifths of maintenance patients may be affected; and it is easily mistaken for opioid withdrawal or for the sweats of the underlying illness. Because sweating in advanced disease has many causes at once, a single opioid is rarely the whole story.

If sweating is new, severe, or accompanied by fever, weight loss or other symptoms, it is worth discussing with a clinician rather than assuming it is simply a medication effect; the evaluation of unexplained sweats is different from managing a known drug side effect.

Methodology and limitations

This page draws on a peer-reviewed methadone survey (Al-Adwani & Basu 2004) and a case report that reconfirms its 45% reference figure (Hong 2017), a hospice-population survey (Quigley & Baines 1997), and a pharmacology review of drug effects on sweating (Cheshire & Fealey 2008), with palliative-care case literature for mechanism and management. Each figure was traced to its source.

Limitations: the 45% methadone figure comes from a clinical survey in a specific maintenance population and is a reported, single-cohort estimate rather than a pooled prevalence; it should not be generalized to all opioids. Robust class-wide incidence figures for individual opioids (morphine, oxycodone, fentanyl) are not established, because large adverse-event studies typically do not itemize sweating. The hospice figure reflects sweating from all causes, not opioids alone. Association is not proof of causation for any individual. This is general education, not medical advice, and not a basis for changing medication; those decisions belong with a prescribing clinician.

Frequently asked questions

How common is sweating with opioids?

It is best quantified for methadone, where a clinical survey reported excessive sweating in up to about 45% of maintenance patients (Al-Adwani & Basu 2004). Class-wide figures for other opioids are not well established, but sweating is recognized across the opioid class.

Why do opioids make you sweat?

Two mechanisms are proposed: histamine release from mast cells, and a central effect on the brain's temperature set-point, with acetylcholine acting at the sweat glands. The fact that antimuscarinic drugs can reduce the sweating supports the second pathway.

Is opioid sweating the same as withdrawal?

No, though it is easily confused with it. Sweating can occur during steady opioid treatment, not only during withdrawal. Persistent sweating on a stable dose is more consistent with a medication effect than with withdrawal, but a clinician should sort this out.

Does switching opioids stop the sweating?

Often not. Because sweating appears to be a shared class effect, opioid rotation frequently does not resolve it, which is why clinicians may instead consider symptom-directed measures. Any change should be made with a prescriber.

When should sweating be checked by a doctor?

If sweating is new, drenching, one-sided, or comes with fever, weight loss, or night sweats, it is worth a clinical review. Unexplained sweats have many possible causes beyond medication and warrant evaluation.

Sources

Primary peer-reviewed studies and official sources first, then reviews and institutional framing (secondary).

1. Al-Adwani A, Basu N. Methadone and excessive sweating. Addiction. 2004;99(2):259. Reported excessive sweating in up to ~45% of methadone-maintenance patients. Journal (Addiction)
2. Hong LI, Lee JSW, Vaidya SA, et al. Methadone-Induced Hyperhidrosis Treated With Oxybutynin. J Addict Med. 2017;11(4):333–334. States methadone-induced excessive sweating affects up to 45% of those prescribed methadone. Full text (PMC)
3. Quigley CS, Baines M. Descriptive epidemiology of sweating in a hospice population. J Palliat Care. 1997;13(1):22–26. 16 of 100 admissions volunteered sweating; 12 severe. PubMed
4. Cheshire WP, Fealey RD. Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management. Drug Saf. 2008;31(2):109–126. Lists opioids among recognized causes of drug-induced hyperhidrosis. PubMed
5. Mercadante S. Hyoscine in opioid-induced sweating. J Pain Symptom Manage. 1998;15(4):214–215. (secondary) PubMed
6. Caflisch C, Figner B, Eich D. Biperiden for excessive sweating from methadone. Am J Psychiatry. 2003;160(2):386–387. (secondary) Journal

How to cite this page

Related reading on this site

• Drug-induced hyperhidrosis: an evidence overview by class
• Antidepressants and sweating: incidence by drug class
• Night sweats in primary care: prevalence and evaluation
• Are night sweats serious?
• Night sweats: the topic hub